Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Publications

  • Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012; 287(30): 25266-79.
  • Baker MP, Reynolds H, Lumisci B and Bryson C. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self/Non-Self. 2010; 1(4):314-322
  • Baker MP and Carr F. J. Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics. Current Drug Safety. 2010; 5(4):308-13
  • Bryson C, Jones TD and Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. Biodrugs 2010; 24(1): 1-8
  • Jones TD, Crompton LJ, Carr FJ, Baker MP. Deimmunization of monoclonal antibodies. Methods Mol Biol. 2009;525:405-23
  • Carr FJ and Baker MP (2009). In vitro screening for antibody immunogenicity. In M. Little (Ed), Recombinant Antibodies (pp.43). Cambridge, UK, Cambridge University.
  • Holgate RG, Baker MP.Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs. 2009; 12(4):233-7.
  • Perry LCA, Jones TD and Baker MP. New approaches to prediction of immune responses to therapeutic proteins in early development. Drugs in R&D 2008; 9(6):385-96
  • Jones TD, Crompton LJ, Carr FJ, and Baker MP. Deimmunisation of monoclonal antibodies. Methods in Molecular Biology. 2009; 525:405-23
  • Baker M, and Jones TD. The identification and removal of immunogenicity in therapeutic proteins. Curr. Opin. Drug Discovery Dev. 2007; (2007); 10(2): 219-227.
  • Jaber A, and Baker M. Assessment of immunogenicity of different interferon beta-1a formulations using ex vivo assays. J. Pharma. Biomed. Anal. 2007; 43(4): 1256-1261.
  • Chester K.A., Baker M. and Mayer A. Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev. Clin. Immunol. 2005; 1(4), 549-559.
  • Jones TD, Philips W, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston GSH, Baker MP. Identification and removal of a CD4+ T cell epitope from the C1 domain of factor VIII. J Thrombosis and Haemostasis. 2005; 3(5):991-1000.
  • Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, Lo KM, Gillies SD, Carr FJ, Baker MP. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res. 2004; 24(9): 560-72.